# Trial of 6% HES130/0.4

> **NCT01010022** · PHASE3 · COMPLETED · sponsor: **Fresenius Kabi Japan** · enrollment: 64 (actual)

## Conditions studied

- Hypovolemia
- Hemorrhage

## Interventions

- **DRUG:** 6% hydroxyethyl starch 130/0.4
- **DRUG:** 6% hydroxyethyl starch 70/0.5 (Salinhes®)

## Key facts

- **NCT ID:** NCT01010022
- **Lead sponsor:** Fresenius Kabi Japan
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-11
- **Primary completion:** 2010-07
- **Final completion:** 2010-11
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2011-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01010022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01010022, "Trial of 6% HES130/0.4". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01010022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*